Travere Therapeutics, Inc. and Viridian Therapeutics, Inc.: A Comprehensive Revenue Analysis

Biotech Revenue Trends: Travere vs. Viridian (2014-2023)

__timestampTravere Therapeutics, Inc.Viridian Therapeutics, Inc.
Wednesday, January 1, 2014282032054320000
Thursday, January 1, 2015998920002538000
Friday, January 1, 20161335910003337000
Sunday, January 1, 20171549370004003000
Monday, January 1, 20181642460008386000
Tuesday, January 1, 20191753380004461000
Wednesday, January 1, 20201983210001050000
Friday, January 1, 20212274900002963000
Saturday, January 1, 20222120180001772000
Sunday, January 1, 2023145238000314000
Loading chart...

Cracking the code

A Tale of Two Biotechs: Revenue Trends from 2014 to 2023

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success and potential. Over the past decade, Travere Therapeutics, Inc. has demonstrated a robust revenue trajectory, with a remarkable increase of over 400% from 2014 to 2021. This growth peaked in 2021, with revenues reaching their zenith. However, 2023 saw a decline, bringing revenues down by approximately 36% from the previous year.

In contrast, Viridian Therapeutics, Inc. has experienced a more volatile revenue journey. Starting with modest figures in 2014, the company saw its highest revenue in 2018, only to face a significant downturn in subsequent years, culminating in a 92% drop by 2023. This analysis highlights the contrasting paths of these two companies, offering insights into the challenges and opportunities within the biotech sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025